Some 7 analysts have recommended on the stock of TherapeuticsMD Inc. (NYSE MKT:TXMD) so far and from them the equity has an average call of Buy. But what does that indicate? It deciphers analysts? recommendations; shareholders should know that 1.00 – 1.24 implies that a stock is a BUY. Call of 1.75 – 2.24 implies that an equity is a HOLD. SELL recommendation is represented by numbers 2.75 – 3.00.
Let’s look into the technical of the stock
The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak.
As for the price, analysts project that shares of TherapeuticsMD Inc. will be trading around $16.14 in the next 12 months.
The stock price is influenced by the financial performance and represents investors opinion of its future. That being the case, shareholders should recall that TherapeuticsMD Inc. posted EPS of $(0.11) in its recent quarter.
The firm recorded the EPS from sales of 3.99M%, which increased -0.24%% from a same period a year ago.
TherapeuticsMD Inc. incurred expenses totaling $709,334 to produce the revenue. Gross profit, which is computed by deducting cost of sales from sales, was $3.28M.
Analysts on the average are projecting TherapeuticsMD Inc. to post EPS of $-0.11 in the ongoing quarter.
Does TherapeuticsMD Inc. have the capacity to surpass expectations? Casting an eye on the firm’s liquidity position, you note that the firm generated net cash of $(20.53M) from its operations in the previous quarter, resulting in free cash flow of $(20.55M). Net change in cash came at $(18.01M).
Furthermore, the firm’s asset position was $124.42M at the close of the latest quarter. But TherapeuticsMD Inc. is carrying liabilities totaling $14.09M.
The firm ended the latest quarter with diluted due shares of 197.79M.